NCT07542626 Fertility Restoration With Autografting of Cryopreserved Immature Testicular Tissue
| NCT ID | NCT07542626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Condition | Azoospermia or Severe Oligozoospermia |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-19 |
| Primary Completion | 2035-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-19 with a primary completion date of 2035-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot clinical trial to evaluate the feasibility and outcome of autologous transplantation of immature testicular tissue cryopreserved during childhood as a method of fertility preservation for prepubertal boys in case of gonadotoxic therapies. Freezing of immature testicular tissue is performed since the early 2000s and a number of our patients have now reached reproductive age. In case of childwish and azoospermia in adulthood, surgical sperm retrieval is planned and if unsucessful transplantation of the patient's own cryopreserved tissue will be performed during the same surgical intervention as a fertility restoration method.
Eligibility Criteria
Inclusion Criteria: all are required * patients who have completed their gonadotoxic treatment * patients who are in good health after care of the primary disease based on hemato-oncologist input * patients with proven azoospermia in adulthood and child's wish requesting transplantation * patients who cryopreserved and stored their immature testicular tissue (in conformity with regulatory requirements) * in case of prior hematological malignant disease or metatstatic cancer, if the multidisciplinary assesment considers the risk of cancer cell contamination is negligible Exclusion Criteria: * patients for whom the cryostored tissue presents a non-negligible risk of cancer cells contamination * patients presenting with a contraindication for general anethesia
Contact & Investigator
Christine Wyns, MD, PhD
PRINCIPAL INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Frequently Asked Questions
Who can join the NCT07542626 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 40 Years, studying Azoospermia or Severe Oligozoospermia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07542626 currently recruiting?
Yes, NCT07542626 is actively recruiting participants. Contact the research team at christine.wyns@saintluc.uclouvain.be for enrollment information.
Where is the NCT07542626 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT07542626 clinical trial?
NCT07542626 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The principal investigator is Christine Wyns, MD, PhD at Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The trial plans to enroll 20 participants.